Boc-D-Ala-Gly-OBzl | 64410-44-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-D-Ala-Gly-OBzl
• 英文别名: Boc-(D)Ala-Gly-OBzl；benzyl 2-[[(2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]acetate
• CAS: 64410-44-2
• 化学式: C₁₇H₂₄N₂O₅
• 分子量: 336.388
• InChiKey: JNYKZWBVTXFUBQ-GFCCVEGCSA-N

物化性质

• 熔点：
  88-89 °C
• 沸点：
  506.2±35.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  93.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Boc-D-Ala-Gly-OBzl 生成 Boc-Tyr-(D)Ala-Gly-OBzl
  参考文献：
  名称：

  BAUER, W.;CARDINAUX, F.;HUGUENIN, R.;PLESS, J.;SANDRIN, E.

  摘要：

  DOI：
• 作为产物：
  描述：

  甘氨酸苄酯盐酸盐 、 BOC-D-丙氨酸 生成 Boc-D-Ala-Gly-OBzl
  参考文献：
  名称：

  YAGI, KUNIO;SIMATO, JOSIYUKI;VAKI, MITINORI;KATO, TEHTSUO;KOYA, NOBUO

  摘要：

  DOI：

文献信息

• One-pot mechanosynthesis of aromatic amides and dipeptides from carboxylic acids and amines
  作者：Vjekoslav Štrukil、Boris Bartolec、Tomislav Portada、Ivica Đilović、Ivan Halasz、Davor Margetić

  DOI：10.1039/c2cc36613d

  日期：——

  Environmentally friendly one-pot synthesis of amides, bis-amides and dipeptides by mechanochemical carbodiimide-mediated coupling of carboxylic acids and amines is described; high reaction yields and simple aqueous work-up allow for the clean, practical and fast preparation of a variety of compounds containing the amide bond from readily accessible reagents.

  通过机械化学碳二亚胺介导的羧酸和胺的偶联，描述了环境友好的一锅合成酰胺，双酰胺和二肽。高反应产率和简单的水后处理使得可以从容易获得的试剂中清洁，实用，快速地制备各种含有酰胺键的化合物。
• Amino Acids and Peptides. XXIV. Preparation and Antinociceptive Effect of (D-Ala2,(N-Me)Phe4)Enkephalin Analog-Poly(Ethylene Glycol) Hybrids.
  作者：Mitsuko MAEDA、Koichi KAWASAKI、Masakatsu TAKAHASHI、Kaoru NAKAO、Hiroshi KANETO

  DOI：10.1248/cpb.42.1859

  日期：——

  Hybrids of amino-poly(ethylene glycol) (a PEG) and [D-Ala2, (N-Me)Phe4]enkephalin analogs, H-Tyr-D-Ala-Gly-(Me)Phe-aPEG, H-Tyr-D-Ala-Gly-(Me)Phe-Leu-aPEG and H-Tyr-D-Ala-Gly-(Me)Phe-D-Leu-aPEG, were prepared by the solution method and their antinociceptive properties were examined in comparison with those of the peptides. H-Tyr-D-Ala-Gly-(Me)Phe-OH and H-Tyr-D-Ala-Gly-(Me)Phe-Leu-OH themselves at intracerebroventricular (i.c.v.) doses of 10-30nmol/animal produced an antinociceptive effect which was less potent than that of i.c.v. morphine, 3μg/animal, and H-Tyr-D-Ala-Gly-(Me)Phe-D-Leu-OH did not have any marked effect. However, the antinociceptive effects of H-Tyr-D-Ala-Gly-(Me)Phe-Leu-OH and H-Tyr-D-Ale-Gly-(Me)Phe-D-Leu-OH were remarkably potentiated by hybrid formation with aPEG to levels higher than that of 3μg/mouse of morphine, and the effect lasted at least 120min. In contrast, the effect of H-Tyr-D-Ala-Gly-(Me)Phe-OH was rather diminished by hybrid formation. In view of the low toxicity and weak immunogeic properties of aPEG, the hybrids could be useful in therapy of patients for relieving chronic and severe pain.

  通过溶液法制备了氨基聚乙二醇（PEG）和[D-Ala2, (N-Me)Phe4]enkephalin 类似物的混合物，即 H-Tyr-D-Ala-Gly-(Me)Phe-aPEG、H-Tyr-D-Ala-Gly-(Me)Phe-Leu-aPEG 和 H-Tyr-D-Ala-Gly-(Me)Phe-D-Leu-aPEG，并与多肽的抗痛觉特性进行了比较。H-Tyr-D-Ala-Gly-(Me)Phe-OH和H-Tyr-D-Ala-Gly-(Me)Phe-Leu-OH本身在脑内注射（i.c.v.）剂量为10-30nmol/只动物时产生的抗痛觉作用不如静脉注射吗啡（3μg/只动物），而H-Tyr-D-Ala-Gly-(Me)Phe-D-Leu-OH则没有明显的作用。然而，H-Tyr-D-Ala-Gly-(Me)Phe-D-Leu-OH和H-Tyr-D-Ale-Gly-(Me)Phe-D-Leu-OH与aPEG形成杂交后，其抗痛作用明显增强，水平高于3微克/只小鼠吗啡的作用，且作用至少持续120分钟。相比之下，H-Tyr-D-Ala-Gly-(Me)Phe-OH 的作用则因杂交形成而减弱。鉴于 aPEG 的低毒性和弱免疫基因特性，这些杂交化合物可用于缓解慢性和严重疼痛患者的治疗。
• Antiviral Immunotropic Agent for the Treatment of Acute Respiratory Viral Infections
  申请人：PVP LABS PTE. LTD.

  公开号：US20190322701A1

  公开（公告）日：2019-10-24

  The proposed methods of treatment pertain to medicine, in particular pharmacology, and concerns the application of a nasal medicinal composition containing hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine or its pharmaceutically acceptable salt for the treatment of acute respiratory viral infections (ARVIs), in particular those caused by the influenza virus.

  提议的治疗方法涉及医学，特别是药理学，涉及应用含有六肽基酪氨酸-D-丙氨酰-甘氨酰-苯丙氨酰-亮氨酰-精氨酸或其药学上可接受的盐的鼻用药物组合物，用于治疗急性呼吸道病毒感染（ARVIs），特别是由流感病毒引起的感染。
• Novel peptide
  申请人：Ajinomoto Co., Inc.

  公开号：US04670540A1

  公开（公告）日：1987-06-02

  Peptides represented by the formula: ##STR1## wherein: X represents Met, Met(O), Nle, or Ile; Y represents a cystine residue or an .alpha.-amino suberic acid residue; Z represents Gly or Ala; m, n, and p each represent 0 or 1; A represents Ser, Ser-Ser, Arg-Ser-Ser, Arg-Arg-Ser-Ser, Leu-Arg-Arg-Ser-Ser, or Ser-Leu-Arg-Arg-Ser-Ser; and B represents Asn, Asn-Ser, Asn-Ser-Phe, Asn-Ser-Phe-Arg, or Asn-Ser-Phe-Arg-Tyr; with the proviso that .alpha.-hANP(1-28), .alpha.-rANP(1-28), .alpha.-rANP(4-28), .alpha.-rANP(5-27), .alpha.-rANP(5-25), and .alpha.-rANP(3-28) are excluded from the compounds represented by the formula are disclosed along with methods of using these compounds.

  公式所代表的肽类：##STR1## 其中：X代表Met，Met（O），Nle或Ile; Y代表半胱氨酸残基或α-氨基戊二酸残基; Z代表Gly或Ala; m，n和p每个表示0或1; A代表Ser，Ser-Ser，Arg-Ser-Ser，Arg-Arg-Ser-Ser，Leu-Arg-Arg-Ser-Ser或Ser-Leu-Arg-Arg-Ser-Ser; B代表Asn，Asn-Ser，Asn-Ser-Phe，Asn-Ser-Phe-Arg或Asn-Ser-Phe-Arg-Tyr; 前提是α-hANP（1-28），α-rANP（1-28），α-rANP（4-28），α-rANP（5-27），α-rANP（5-25）和α-rANP（3-28）由该公式所代表的化合物中排除，并公开了使用这些化合物的方法。
• Atrial natriuretic peptide derivative
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05159061A1

  公开（公告）日：1992-10-27

  A peptide derivative of the formula ##STR1## wherein A is hydrogen or a hydrocarbon acyl having 2 to 18 carbon atoms which is substituted by an amino group at the .alpha.-position; B is F-Gly wherein F is a neutral .alpha.-amino acid residue, or NH-(CH.sub.2)nCO wherein n is an integer of 1 to 4; C is a neutral .alpha.-amino acid residue; and E is L-Arg or D-Arg; when A, B and C are hydrogen, Gly-Gly, and Met or Ile, respectively, E is D-Arg, or its pharmacologically acceptable salt has strong hypotensive and natriuretic activity; therefore it is useful as a therapeutic drug for hypertension, a diuretic, and a therapeutic drug for cardiac and cerebral circulatory diseases.

  一种肽衍生物的公式为 ##STR1## 其中A是氢或具有2至18个碳原子的烃基酰基，该烃基酰基在α位上被氨基取代; B是F-Gly，其中F是中性的α-氨基酸残基，或NH-(CH.sub.2)nCO，其中n是1至4的整数; C是中性的α-氨基酸残基; 而E是L-Arg或D-Arg; 当A、B和C为氢、Gly-Gly和Met或Ile时，E为D-Arg，或其药理学上可接受的盐具有强烈的降压和利尿活性; 因此，它可用作治疗高血压、利尿剂、心脏和脑循环疾病的治疗药物。